Advertisement
American Journal of Kidney Diseases

Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial

      Rationale & Objective

      Hypokalemia is a common electrolyte abnormality in patients on peritoneal dialysis (PD) and has been associated with increased risks of peritonitis and death. Whether correction of hypokalemia improves these outcomes is unknown.

      Study Design

      Multicenter, open-label, prospective, randomized controlled trial.

      Setting & Participants

      Adult (aged ≥18 years) PD patients with hypokalemia (defined as at least 3 values or an average value <3.5 mEq/L in the past 6 months). Randomization was stratified according to center and residual urine output (≤100 or >100 mL/day).

      Interventions

      Random assignment to either protocol-based potassium supplementation (titratable dose of oral potassium chloride to maintain serum potassium of 4-5 mEq/L) or conventional potassium supplementation (reactive supplementation when serum potassium is <3.5 mEq/L) over 52 weeks. Treatment groups were compared using intention-to-treat analyses implemented using Cox proportional hazards regression.

      Outcome

      The primary outcome was time from randomization to first peritonitis episode (any organism). Secondary outcomes were all-cause mortality, cardiovascular mortality, hospitalization, and conversion to hemodialysis.

      Results

      A total of 167 patients with time-averaged serum potassium concentrations of 3.33 ± 0.28 mEq/L were enrolled from 6 PD centers: 85 were assigned to receive protocol-based treatment, and 82 were assigned to conventional treatment. The median follow-up time was 401 (IQR, 315-417) days. During the study period, serum potassium levels in the protocol-based treatment group increased to 4.36 ± 0.70 mEq/L compared with 3.57 ± 0.65 mEq/L in the group treated conventionally (mean difference, 0.66 [95% CI, 0.53-0.79] mEq/L; P < 0.001). The median time to first peritonitis episode was significantly longer in the protocol-based group (223 [IQR, 147-247] vs 133 [IQR, 41-197] days, P = 0.03). Compared with conventional treatment, the protocol-based group had a significantly lower hazard of peritonitis (HR, 0.47 [95% CI, 0.24-0.93]) but did not differ significantly with respect to any of the secondary outcomes. Asymptomatic hyperkalemia (>6 mEq/L) without characteristic electrocardiographic changes occurred in 3 patients (4%) in the protocol-based treatment group.

      Limitations

      Not double-masked.

      Conclusions

      Compared with reactive potassium supplementation when the serum potassium level falls below 3.5 mEq/L, protocol-based oral potassium treatment to maintain a serum potassium concentration in the range of 4-5 mEq/L may reduce the risk of peritonitis in patients receiving PD who have hypokalemia.

      Trial Registration

      Registered at the Thai Clinical Trials Registry with study number TCTR20190725004.

      Graphical abstract

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jha V.
        • Garcia-Garcia G.
        • Iseki K.
        • et al.
        Chronic kidney disease: global dimension and perspectives.
        Lancet. 2013; 382: 260-272https://doi.org/10.1016/S0140-6736(13)60687-X
        • Liyanage T.
        • Ninomiya T.
        • Jha V.
        • et al.
        Worldwide access to treatment for end-stage kidney disease: a systematic review.
        Lancet. 2015; 385: 1975-1982https://doi.org/10.1016/S0140-6736(14)61601-9
        • Xie Y.
        • Bowe B.
        • Mokdad A.H.
        • et al.
        Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016.
        Kidney Int. 2018; 94: 567-581https://doi.org/10.1016/j.kint.2018.04.011
        • Kanjanabuch T.
        • Takkavatakarn K.
        Global dialysis perspective: Thailand.
        Kidney360. 2020; 1: 671-675https://doi.org/10.34067/KID.0000762020
        • Torlen K.
        • Kalantar-Zadeh K.
        • Molnar M.Z.
        • Vashistha T.
        • Mehrotra R.
        Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort.
        Clin J Am Soc Nephrol. 2012; 7: 1272-1284https://doi.org/10.2215/CJN.00960112
        • Davies S.J.
        • Zhao J.
        • Morgenstern H.
        • et al.
        Low serum potassium levels and clinical outcomes in peritoneal dialysis—international results from PDOPPS.
        Kidney Int Rep. 2020; 6: 313-324https://doi.org/10.1016/j.ekir.2020.11.021
        • Szeto C.C.
        • Chow K.M.
        • Kwan B.C.
        • et al.
        Hypokalemia in Chinese peritoneal dialysis patients: prevalence and prognostic implication.
        Am J Kidney Dis. 2005; 46: 128-135https://doi.org/10.1053/j.ajkd.2005.03.015
        • Vavruk A.M.
        • Martins C.
        • Nascimento M.M.
        • Hayashi S.Y.
        • Riella M.C.
        Association between hypokalemia, malnutrition and mortality in peritoneal dialysis patients.
        J Bras Nefrol. 2012; 34: 349-354https://doi.org/10.5935/0101-2800.20120024
        • Ribeiro S.C.
        • Figueiredo A.E.
        • Barretti P.
        • Pecoits-Filho R.
        • de Moraes T.P.
        Low serum potassium levels increase the infectious-caused mortality in peritoneal dialysis patients: a propensity-matched score study.
        PLoS One. 2015; 10e0127453https://doi.org/10.1371/journal.pone.012745310
        • Virojanawat M.
        • Puapatanakul P.
        • Chuengsaman P.
        • et al.
        Hypokalemia in peritoneal dialysis patients in Thailand: the pivotal role of low potassium intake.
        Int Urol Nephrol. 2021; 53: 1463-1471https://doi.org/10.1007/s11255-020-02773-8
        • Chuang Y.W.
        • Shu K.H.
        • Yu T.M.
        • Cheng C.H.
        • Chen C.H.
        Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients.
        Nephrol Dial Transplant. 2009; 24: 1603-1608https://doi.org/10.1093/ndt/gfn709
        • Li P.K.
        • Szeto C.C.
        • Piraino B.
        • et al.
        ISPD peritonitis recommendations: 2016 update on prevention and treatment.
        Perit Dial Int. 2016; 36: 481-508https://doi.org/10.3747/pdi.2016.00078
        • Manera K.E.
        • Johnson D.W.
        • Craig J.C.
        • et al.
        Establishing a core outcome set for peritoneal dialysis: report of the SONG-PD (Standardized Outcomes in Nephrology-Peritoneal Dialysis) Consensus Workshop.
        Am J Kidney Dis. 2020; 75: 404-412https://doi.org/10.1053/j.ajkd.2019.09.017
        • Dupont W.D.
        • Plummer Jr., W.D.
        Power and sample size calculations: a review and computer program.
        Control Clin Trials. 1990; 11: 116-128https://doi.org/10.1016/0197-2456(90)90005-m
        • Schoenfeld D.A.
        • Richter J.R.
        Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint.
        Biometrics. 1982; 38: 163-170https://doi.org/10.2307/2530299
        • Boudville N.
        • Johnson D.W.
        • Zhao J.
        • et al.
        Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study.
        Nephrol Dial Transplant. 2019; 34: 2118-2126https://doi.org/10.1093/ndt/gfy204
        • Nakai K.
        • Saito K.
        • Fujii H.
        • Nishi S.
        Impact of hypokalemia on peritonitis in peritoneal dialysis patients: a systematic review.
        Ren Replace Ther. 2017; 3: 43https://doi.org/10.1186/s41100-017-0128-5
        • Pichitporn W.
        • Puapatanakul P.
        • Phannajit J.
        • et al.
        Effectiveness of potassium supplement in hypokalemic PD patients: a stratified randomized controlled trial [abstract 43 O040].
        Nephrology. 2021; 26: 3-31https://doi.org/10.1111/nep.13943

      Linked Article

      • Correction of Hypokalemia in Peritoneal Dialysis Patients May Decrease Peritonitis Risk
        American Journal of Kidney DiseasesVol. 80Issue 5
        • Preview
          While interest in peritoneal dialysis (PD) is growing in many parts of the world given its patient-centric approach and favorable cost profile, peritonitis remains a major problem. Some risk factors have been identified, but many of these are not modifiable. One that deserves closer scrutiny is hypokalemia, which has been associated with an increased risk for peritonitis.1-3 The impact of treatment of hypokalemia on peritonitis risk has not been previously closely examined.
        • Full-Text
        • PDF